domingo, 26 de junio de 2016

Telomere and Telomerase Therapeutics in Cancer. - PubMed - NCBI

Telomere and Telomerase Therapeutics in Cancer. - PubMed - NCBI

 2016 May 26;7(6). pii: E22. doi: 10.3390/genes7060022.

Telomere and Telomerase Therapeutics in Cancer.


Telomerase is a reverse transcriptase capable of utilizing an integrated RNA component as a template to add protective tandem telomeric single strand DNA repeats, TTAGGG, to the ends of chromosomes. Telomere dysfunction and telomerase reactivation are observed in approximately 90% of human cancers; hence, telomerase activation plays a unique role as a nearly universal step on the path to malignancy. In the past two decades, multiple telomerase targeting therapeutic strategies have been pursued, including direct telomerase inhibition, telomerase interference, hTERT or hTERC promoter driven therapy, telomere-based approaches, and telomerase vaccines. Many of these strategies have entered clinical development, and some have now advanced to phase III clinical trials. In the coming years, one or more of these new telomerase-targeting drugs may be expected to enter the pharmacopeia of standard care. Here, we briefly review the molecular functions of telomerase in cancer and provide an update about the preclinical and clinical development of telomerase targeting therapeutics.


targeted therapy; telomerase; telomeres

Free full text

No hay comentarios:

Publicar un comentario